Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug Administration approval, marking the first substantive pharmacological innovation in over two decades and catalyzing a fundamental paradigm shift from empirical symptom management towards biomarker‐driven, pathobiology‐aligned precision medicine. In this comprehensive review, we synthesized emerging evidence on novel COPD therapeutics, encompassing dual phosphodiesterase‐3/4 inhibitors, biologics targeting type 2 inflammatory pathways (interleukin [IL]‐4/IL‐13 and IL‐5 axes), upstream alarmin antagonists (IL‐33 and thymic stromal lymphopoietin), and emerging technologies including gene editing and senolytic therapy. We evaluated randomized controlled trials reporting reductions in exacerbations with biologic therapy in eosinophil‐enriched populations. Central to this transformation is the “treatable traits” framework, in which COPD management shifts from categorical diagnosis towards identification and targeting of specific, modifiable pathobiological characteristics. We provide respiratory physicians with evidence‐based guidance for treatment selection by leveraging validated biomarkers, discussing pharmacoeconomic considerations and implementation barriers in resource‐limited settings, and identifying critical knowledge gaps requiring resolution. The convergence of biologics, small molecules, and emerging technologies positions COPD therapeutics at the threshold of disease modification.